Cargando…

Repertoires of SARS-CoV-2 epitopes targeted by antibodies vary according to severity of COVID-19

Antibodies to SARS-CoV-2 are central to recovery and immunity from COVID-19. However, the relationship between disease severity and the repertoire of antibodies against specific SARS-CoV-2 epitopes an individual develops following exposure remains incompletely understood. Here, we studied seropreval...

Descripción completa

Detalles Bibliográficos
Autores principales: Gregory, David J., Vannier, Augustin, Duey, Akiro H., Roady, Tyler J., Dzeng, Richard K., Pavlovic, Maia N., Chapin, Michael H., Mukherjee, Sonia, Wilmot, Hannah, Chronos, Nic, Charles, Richelle C., Ryan, Edward T., LaRocque, Regina C., Miller, Tyler E., Garcia-Beltran, Wilfredo F., Thierauf, Julia C., Iafrate, A. John, Mullenbrock, Steven, Stump, Mark D., Wetzel, Randall K., Polakiewicz, Roberto D., Naranbhai, Vivek, Poznansky, Mark C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9122311/
https://www.ncbi.nlm.nih.gov/pubmed/35587156
http://dx.doi.org/10.1080/21505594.2022.2073025
_version_ 1784711318585999360
author Gregory, David J.
Vannier, Augustin
Duey, Akiro H.
Roady, Tyler J.
Dzeng, Richard K.
Pavlovic, Maia N.
Chapin, Michael H.
Mukherjee, Sonia
Wilmot, Hannah
Chronos, Nic
Charles, Richelle C.
Ryan, Edward T.
LaRocque, Regina C.
Miller, Tyler E.
Garcia-Beltran, Wilfredo F.
Thierauf, Julia C.
Iafrate, A. John
Mullenbrock, Steven
Stump, Mark D.
Wetzel, Randall K.
Polakiewicz, Roberto D.
Naranbhai, Vivek
Poznansky, Mark C.
author_facet Gregory, David J.
Vannier, Augustin
Duey, Akiro H.
Roady, Tyler J.
Dzeng, Richard K.
Pavlovic, Maia N.
Chapin, Michael H.
Mukherjee, Sonia
Wilmot, Hannah
Chronos, Nic
Charles, Richelle C.
Ryan, Edward T.
LaRocque, Regina C.
Miller, Tyler E.
Garcia-Beltran, Wilfredo F.
Thierauf, Julia C.
Iafrate, A. John
Mullenbrock, Steven
Stump, Mark D.
Wetzel, Randall K.
Polakiewicz, Roberto D.
Naranbhai, Vivek
Poznansky, Mark C.
author_sort Gregory, David J.
collection PubMed
description Antibodies to SARS-CoV-2 are central to recovery and immunity from COVID-19. However, the relationship between disease severity and the repertoire of antibodies against specific SARS-CoV-2 epitopes an individual develops following exposure remains incompletely understood. Here, we studied seroprevalence of antibodies to specific SARS-CoV-2 and other betacoronavirus antigens in a well-annotated, community sample of convalescent and never-infected individuals obtained in August 2020. One hundred and twenty-four participants were classified into five groups: previously exposed but without evidence of infection, having no known exposure or evidence of infection, seroconverted without symptoms, previously diagnosed with symptomatic COVID-19, and recovered after hospitalization with COVID-19. Prevalence of IgGs specific to the following antigens was compared between the five groups: recombinant SARS-CoV-2 and betacoronavirus spike and nucleocapsid protein domains, peptides from a tiled array of 22-mers corresponding to the entire spike and nucleocapsid proteins, and peptides corresponding to predicted immunogenic regions from other proteins of SARS-CoV-2. Antibody abundance generally correlated positively with severity of prior illness. A number of specific immunogenic peptides and some that may be associated with milder illness or protection from symptomatic infection were identified. No convincing association was observed between antibodies to Receptor Binding Domain(s) (RBDs) of less pathogenic betacoronaviruses HKU1 or OC43 and COVID-19 severity. However, apparent cross-reaction with SARS-CoV RBD was evident and some predominantly asymptomatic individuals had antibodies to both MERS-CoV and SARS-CoV RBDs. Findings from this pilot study may inform development of diagnostics, vaccines, and therapeutic antibodies, and provide insight into viral pathogenic mechanisms.
format Online
Article
Text
id pubmed-9122311
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-91223112022-05-21 Repertoires of SARS-CoV-2 epitopes targeted by antibodies vary according to severity of COVID-19 Gregory, David J. Vannier, Augustin Duey, Akiro H. Roady, Tyler J. Dzeng, Richard K. Pavlovic, Maia N. Chapin, Michael H. Mukherjee, Sonia Wilmot, Hannah Chronos, Nic Charles, Richelle C. Ryan, Edward T. LaRocque, Regina C. Miller, Tyler E. Garcia-Beltran, Wilfredo F. Thierauf, Julia C. Iafrate, A. John Mullenbrock, Steven Stump, Mark D. Wetzel, Randall K. Polakiewicz, Roberto D. Naranbhai, Vivek Poznansky, Mark C. Virulence Research Paper Antibodies to SARS-CoV-2 are central to recovery and immunity from COVID-19. However, the relationship between disease severity and the repertoire of antibodies against specific SARS-CoV-2 epitopes an individual develops following exposure remains incompletely understood. Here, we studied seroprevalence of antibodies to specific SARS-CoV-2 and other betacoronavirus antigens in a well-annotated, community sample of convalescent and never-infected individuals obtained in August 2020. One hundred and twenty-four participants were classified into five groups: previously exposed but without evidence of infection, having no known exposure or evidence of infection, seroconverted without symptoms, previously diagnosed with symptomatic COVID-19, and recovered after hospitalization with COVID-19. Prevalence of IgGs specific to the following antigens was compared between the five groups: recombinant SARS-CoV-2 and betacoronavirus spike and nucleocapsid protein domains, peptides from a tiled array of 22-mers corresponding to the entire spike and nucleocapsid proteins, and peptides corresponding to predicted immunogenic regions from other proteins of SARS-CoV-2. Antibody abundance generally correlated positively with severity of prior illness. A number of specific immunogenic peptides and some that may be associated with milder illness or protection from symptomatic infection were identified. No convincing association was observed between antibodies to Receptor Binding Domain(s) (RBDs) of less pathogenic betacoronaviruses HKU1 or OC43 and COVID-19 severity. However, apparent cross-reaction with SARS-CoV RBD was evident and some predominantly asymptomatic individuals had antibodies to both MERS-CoV and SARS-CoV RBDs. Findings from this pilot study may inform development of diagnostics, vaccines, and therapeutic antibodies, and provide insight into viral pathogenic mechanisms. Taylor & Francis 2022-05-19 /pmc/articles/PMC9122311/ /pubmed/35587156 http://dx.doi.org/10.1080/21505594.2022.2073025 Text en © 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Paper
Gregory, David J.
Vannier, Augustin
Duey, Akiro H.
Roady, Tyler J.
Dzeng, Richard K.
Pavlovic, Maia N.
Chapin, Michael H.
Mukherjee, Sonia
Wilmot, Hannah
Chronos, Nic
Charles, Richelle C.
Ryan, Edward T.
LaRocque, Regina C.
Miller, Tyler E.
Garcia-Beltran, Wilfredo F.
Thierauf, Julia C.
Iafrate, A. John
Mullenbrock, Steven
Stump, Mark D.
Wetzel, Randall K.
Polakiewicz, Roberto D.
Naranbhai, Vivek
Poznansky, Mark C.
Repertoires of SARS-CoV-2 epitopes targeted by antibodies vary according to severity of COVID-19
title Repertoires of SARS-CoV-2 epitopes targeted by antibodies vary according to severity of COVID-19
title_full Repertoires of SARS-CoV-2 epitopes targeted by antibodies vary according to severity of COVID-19
title_fullStr Repertoires of SARS-CoV-2 epitopes targeted by antibodies vary according to severity of COVID-19
title_full_unstemmed Repertoires of SARS-CoV-2 epitopes targeted by antibodies vary according to severity of COVID-19
title_short Repertoires of SARS-CoV-2 epitopes targeted by antibodies vary according to severity of COVID-19
title_sort repertoires of sars-cov-2 epitopes targeted by antibodies vary according to severity of covid-19
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9122311/
https://www.ncbi.nlm.nih.gov/pubmed/35587156
http://dx.doi.org/10.1080/21505594.2022.2073025
work_keys_str_mv AT gregorydavidj repertoiresofsarscov2epitopestargetedbyantibodiesvaryaccordingtoseverityofcovid19
AT vannieraugustin repertoiresofsarscov2epitopestargetedbyantibodiesvaryaccordingtoseverityofcovid19
AT dueyakiroh repertoiresofsarscov2epitopestargetedbyantibodiesvaryaccordingtoseverityofcovid19
AT roadytylerj repertoiresofsarscov2epitopestargetedbyantibodiesvaryaccordingtoseverityofcovid19
AT dzengrichardk repertoiresofsarscov2epitopestargetedbyantibodiesvaryaccordingtoseverityofcovid19
AT pavlovicmaian repertoiresofsarscov2epitopestargetedbyantibodiesvaryaccordingtoseverityofcovid19
AT chapinmichaelh repertoiresofsarscov2epitopestargetedbyantibodiesvaryaccordingtoseverityofcovid19
AT mukherjeesonia repertoiresofsarscov2epitopestargetedbyantibodiesvaryaccordingtoseverityofcovid19
AT wilmothannah repertoiresofsarscov2epitopestargetedbyantibodiesvaryaccordingtoseverityofcovid19
AT chronosnic repertoiresofsarscov2epitopestargetedbyantibodiesvaryaccordingtoseverityofcovid19
AT charlesrichellec repertoiresofsarscov2epitopestargetedbyantibodiesvaryaccordingtoseverityofcovid19
AT ryanedwardt repertoiresofsarscov2epitopestargetedbyantibodiesvaryaccordingtoseverityofcovid19
AT larocquereginac repertoiresofsarscov2epitopestargetedbyantibodiesvaryaccordingtoseverityofcovid19
AT millertylere repertoiresofsarscov2epitopestargetedbyantibodiesvaryaccordingtoseverityofcovid19
AT garciabeltranwilfredof repertoiresofsarscov2epitopestargetedbyantibodiesvaryaccordingtoseverityofcovid19
AT thieraufjuliac repertoiresofsarscov2epitopestargetedbyantibodiesvaryaccordingtoseverityofcovid19
AT iafrateajohn repertoiresofsarscov2epitopestargetedbyantibodiesvaryaccordingtoseverityofcovid19
AT mullenbrocksteven repertoiresofsarscov2epitopestargetedbyantibodiesvaryaccordingtoseverityofcovid19
AT stumpmarkd repertoiresofsarscov2epitopestargetedbyantibodiesvaryaccordingtoseverityofcovid19
AT wetzelrandallk repertoiresofsarscov2epitopestargetedbyantibodiesvaryaccordingtoseverityofcovid19
AT polakiewiczrobertod repertoiresofsarscov2epitopestargetedbyantibodiesvaryaccordingtoseverityofcovid19
AT naranbhaivivek repertoiresofsarscov2epitopestargetedbyantibodiesvaryaccordingtoseverityofcovid19
AT poznanskymarkc repertoiresofsarscov2epitopestargetedbyantibodiesvaryaccordingtoseverityofcovid19